摘要
目的:观察慈丹胶囊联合肝动脉化疗栓塞术(TACE)在中、晚期原发性肝癌综合治疗中的作用。方法:将121例中、晚期原发性肝癌患者随机分为2组:联合组64例,采用慈丹胶囊(每次5粒,每日4次)联合TACE治疗;对照组57例,单纯采用TACE治疗。对2组的有效率、生存率、生活质量和免疫功能进行比较评价。结果:治疗后联合组的有效率、1a生存率、甲胎蛋白下降程度均显著高于对照组(P<0.05);联合组的生活质量提高水平显著高于对照组(P<0.01);联合组的T细胞亚群及NK细胞活性显著高于对照组(P<0.01)。结论:慈丹胶囊联合TACE可以提高中、晚期肝癌的疗效和1a生存率,并改善细胞免疫功能,从而提高患者的生活质量。
OBJECTIVE： To evaluate the therapeutic efficacy of Cidan capsule combined with transcather hepatic arterial ehemoembolization（TACE） for patients with advanced hepatocarcinoma.METHODS： A total of 121 patients with advanced hepatocarcinoma were randomly divided into two groups： 64（combined group） were treated with Cidan Capsule（5 granules qid） combined with TACE, and 57 in control group were treated with TACE alone.The effective rate, survival rate, life quality and immune function in the two groups were evaluated. RESULTS： The effective rate, one-year survival rate, and alpha fetoprotein（AFP） reduction rate in the combined group were significantly better than in the control group（P〈0.05）; The life quality in combined group showed a better improvement than in the control gorup（P 〈 0.01） ;cytoaction of T cell subgroup and NK cells in the combined group was significantly higher than in the control group after treatment（P 〈 0.01）. CONCLUSION; Cidan capsule combined with TACE can improve the therapeutic efficacy,one year survival rate,cellular immune function and life quality of patients with advanced hepatoearcinoma.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第33期2619-2621,共3页
China Pharmacy
关键词
慈丹胶囊
中
晚期肝癌
肝动脉化疗栓塞术
联合治疗
临床疗效
Cidan capsule
Advanced hepatocarcinoma
Transcather hepatic arterial chemoembolization（TACE）
Combined therapy
Clinical efficacy
